1. HBW Insight
  2. >>Wellness
  3. >>Business
  4. >>Earnings

Bausch + Lomb’s First Results Look Familiar

First Full-Year Guidance: $3.75bn To $3.8bn Revenues On 4% To 5% Gtowth

 
• By Malcolm Spicer

January-March results Bausch + Lomb reported on 8 June were included in Bausch Health’s results published in May on the same day it closed an IPO shares to separate its eye health and vision care business. Guidance it provided, however, was new and a first for Bausch + Lomb.

• Source: Shutterstock

Bausch + Lomb Corp.’s first-quarter results were unlike any other it will report in future quarters but a mirror image of the results its former parent firm reported for it earlier in the year.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Earnings

Arkopharma Shakes Up Strategy As Supplement Market Competition Intensifies

 
• By Tom Gallen

Arkopharma's parent company Dermapharm is undertaking a strategic shift at the French firm to help it better compete in the dietary supplements market after a tough year.

Swisse Benefits As Supplements Considered ‘Daily Necessity’ In China

 
• By Tom Gallen

Chinese consumers are now routinely taking supplements for a variety of health reasons, helping to drive up sales of the Swisse Plus+ brand by 20% in 2024.

OptiBiotix Benefitting From Popularity Of Anti-Obesity Drugs

 
• By Tom Gallen

Growing use of GLP-1 receptor agonists is having a positive knock-on effect on the dietary supplements market, reports OptiBiotix Health, marketer of the SlimBiome weight management prebiotic.

Haleon Sales Up Despite Weaker Cold & Flu Season

 
• By Tom Gallen

UK-based consumer health giant reports organic sales growth of 5.0% in 2024 as gains for its power brands offset a softer cold & flu season, particularly in the US.

More from Business

Good News? 90-Day Pause On Most Tariff Changes – Bad News? 125% Rate Imposed Against China

 
• By Malcolm Spicer

US businesses across industry sectors remain apprehensive about higher tariffs going into effect on imports from China after three-month pause allowed on other changes.

KKR Expands Health & Beauty Portfolio With Deal For Sweden’s Karo

 
• By Tom Gallen

Consumer health player Karo is changing hands from EQT to KKR in a deal thought to value the Stockholm-based firm at over €2.5bn.

Clasado Divests Bimuno Prebiotic Consumer Brand To UK’s Eleat

 
• By David Ridley

Eleat's acquisition encompasses Clasado's Bimuno finished supplement product line and customer base, but not its Bimuno GOS proprietary galactooligosaccharide prebiotic ingredient.